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Satisfying the Immense Energy Demands of the Body, and the 
Effects of Mutation within the Mitochondrial ATP6 Gene 
 
Michael White* 
Department of Biology 
Lake Forest College 
Lake Forest, Illinois 60045 
 
Summary 
 
The cells constituting the human body require 
immense amounts of energy to power them.  
Occasionally, defects occur within the powerhouse 
of the cell, the mitochondria, that lead to severe and 
often fatal untreatable diseases such as Leigh 
Syndrome (LS) and Neuropathy, Ataxia, and 
Retinitis Pigmentosa (NARP).  Both LS and NARP 
result from the T8993G or T8993C mutations within 
the ATP6 gene in the mitochondrial genome.  
Because mitochondrial genes are maternally 
inherited and the cellular effects of mutation are 
dosage dependent, LS and NARP syndromes have 
mutant thresholds of 90% to 95% and 70% to 90% 
respectively.  Research within the last fifteen years 
has linked the mutation to decreased ATP synthase 
stability, assembly, catalysis, and oxidative stress.  
This review will focus on ATP6 and the T8993G 
mutation. 
 
Introduction 
 
The human body and the individual cells that compose 
it have an immense energy quota to satisfy.  Over time, 
mammalian cells evolved an energy efficient oxidative-
phosphoralation strategy for obtaining the ubiquitous 
energy currency ATP that produces much more energy 
per molecule of glucose than simple glycolysis.  Without 
ATP, cellular function would cease to exist in our cells.  
The powerhouse of the eukaryotic cell is the 
mitochondria, which is a dual-membrane organelle 
thought to have once been a bacterium before 
becoming part of the eukaryotic cell through 
endosymbiosis.  The proper functioning of this 
organelle is critical to the viability of the cell, and if it is 
defective an array of diseases can manifest. 
 Two rare but prominent diseases associated 
with mitochondrial dysfunction are Neuropathy, Ataxia, 
and Retinitis Pigmentosa (NARP) and Leigh Syndrome.  
NARP is characterized by the above features as well as 
developmental impairments, dementia, and sensory 
deficits (Schon et al., 2001).  These patients typically 
live into their thirties and forties (Manfredi et al., 2002).  
Leigh Syndrome (LS) is a fatal encephalopathy 
consisting of neuronal atrophy localized within the 
brainstem and basal ganglia (Ciafaloni et al., 1993).  
Individuals with LS die during infancy and exhibit motor 
and developmental impairments, respiratory deficits, 
and other features associated with the location of 
atrophy (Ciafaloni et al., 1993).  Neither disease is 
treatable.  In common between these diseases is their 
underlying cause; a defective ATP6 gene within the 
mitochondrial genome.  This is an essential gene that 
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will kill any organism/model if knocked-out or under- 
expressed.  
 It is apparent that the inability to satisfy the 
body’s energy requirements is detrimental, but in LS 
and NARP syndromes cellular atrophy is specific rather 
than global.  The predominant hypothesis within the 
field for this specificity has to do with the varying 
energetic demands of different tissues.  The nervous 
system and the brain, in particular, are by far the 
greatest consumers of energy within the body, and for 
good reason.  Neurons are constantly active and 
involved in everything from cognition, sensation, muscle 
regulation, respiration, etc.  Thus, if mutant 
mitochondria are unable to meet the energy 
requirements of neurons but could still provide enough 
for other cell types, neuronal atrophy in LS and NARP 
syndromes is not surprising.  The remainder of this 
review will focus on ATP6 and the effects of mutation 
within the protein this gene encodes. 
 
Mitochondrial Structure and Function 
 
The mitochondrion is a dual-membrane organelle 
consisting of an acidic inter-membrane space 
separated from the less acidic matrix by a highly 
impermeable membrane (Alberts et al., 2004).  
Embedded in the inner-membrane is the electron 
transport chain that consists of the cytochrome 
complexes and the critical ATP synthesizing enzyme 
ATP synthase.  High energy electrons are delivered to 
the electron transport chain via the activated carrier 
molecules NADH and/or FADH2 (NADPH in Plants) 
from the glycolytic and citric acid cycles in the 
cytoplasm (Alberts et al., 2004).  Upon arrival at 
complex I, the electrons are passed down their energy 
gradients while the energy that is subsequently 
released is coupled to pump protons from the matrix 
into the inter-membrane space.  Thus, a proton gradient 
high in potential energy is established.  These protons 
are then allowed to flow down their concentration 
gradient through the enzyme ATP synthase back into 
the matrix.  The energy from the flow of protons through 
ATP synthase is coupled to the un-favorable ADP + Pi 
 ATP reaction.  This mechanism for producing ATP is 
far more efficient than glycolysis alone, yielding over 30 
ATP per molecule of glucose compared to 2 ATP from 
glycolysis (Alberts et al., 2004). 
 
ATP Synthase and ATP6 
 
At the end of the electron transport chain on the inner-
mitochondrial membrane is the enzyme ATP synthase, 
which is solely responsible for all of the ATP produced 
within the mitochondria.  It is important to note that this 
enzyme is also present in the plasma membranes of 
bacteria and in the thylakoid membranes of chloroplasts 
(Noji and Yoshida, 2001).  Essentially, ATP synthase 
couples the energy released from protons flowing down 
their electrochemical gradients to drive mechanical 
rotation of the enzyme and synthesize ATP.  ATP 
synthase has a soluble F1 portion comprised of five 
different subunits that act as the site of catalysis, and 
an insoluble F0 sector embedded in the membrane 
comprised of ten different subunits (Baracca et al., 
2000; Elston et al., 1998).  F1 and F0 are connected via 
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a common rotary shaft (Noji and Yoshida, 2001; Elston 
et al., 1998; Alberts et al., 2004). 
Particularly important is the “a” subunit of F0 
and the 10-14 “c-ring” subunits it is connected to (Noji 
and Yoshida, 2001).  Subunit “a” is encoded by the 
mitochondrial ATP6 gene and forms the channel for 
protons to flow through (referred to as ATP6 
interchangeably) (Elston et al., 1998; Alberts et al., 
2004).  While protons flow through ATP6, they drive the 
rotation of the c-rings and consequently rotate the 
common shaft linking F1 and F0 (Elston et al., 1998; Noji 
and Yoshida, 2001).  This rotational energy is used by 
the  subunit in F1 to synthesize ATP from ADP (Noji 
and Yoshida, 2001; Alberts et al., 2004).  Interestingly, 
this rotary enzyme can operate in reverse (i.e. ATP 
hydrolysis).  The cell carefully controls its supply of 
ATP, not wanting too little or too much of it.  If there is 
too much ATP, simple Brownian motion of the pool of 
ATP and ADP will lead to more ATP binding to the  
subunit on ATP synthase than ADP.  As a result, ATP 
hydrolysis occurs and drives the rotary shaft linking F0 
and F1 in the opposite direction (Elston et al., 1998; 
Alberts et al., 2004).  This results in protons being 
pumped from the matrix into the inter-membrane space 
and stores the excess energy within the proton gradient 
rather than ATP (Elston et al., 1998).  
 
Inheritance and Molecular Genetics of ATP6 
 
Only the ATP6 and ATP8 subunits of ATP synthase are 
encoded in the 16,569 base-pair circular mitochondrial 
genome located in the matrix, while all other subunits 
are in the nuclear genome (Schon et al., 2001; Alberts 
et al., 2004).  Consequently, the inheritance pattern for 
mitochondrial genes is different from that of nuclear 
genes.  The oocyte contains the vast majority of the 
mitochondria that the embryo will receive, and the 
specific mitochondria that are packaged into the egg is 
a random event (Alberts et al., 2004).  Within ATP6 of 
LS and NARP patients there is a T8993G mutation that 
causes leucine156 (neutral) to become arginine 
(positively charged) (Holt et al., 1990), or a much less 
common and studied T8993C mutation (de Vries at al., 
1993).  Therefore, initial studies of LS and NARP 
patients tested for maternal inheritance of the mutant 
ATP6 gene. This mode of inheritance was confirmed by 
Ciafaloni et al. (1993). 
 After confirming maternal inheritance, the 
significant gap in knowledge was determining the 
dosage of mutant mitochondrial DNA (heteroplasmy) 
necessary to cause NARP or Leigh syndromes.  
Because both exhibit distinct clinical and pathological 
phenotypes but are caused by an identical mutation 
within the same gene, there must be a dosage 
necessary to cause disease difference between the 
two.  Tautch et al. performed the first assessment of 
mutant ATP6 heteroplasmy in a family with NARP and 
Leigh syndromes (1992).  They determined that a LS 
patient had greater than 95% T8993G ATP6 DNA in her 
skin fibroblasts, but that her mother who had NARP 
harbored between 71% and 39% T8993G DNA (Tautch 
et al., 1992).  The LS patient’s uncle also had NARP 
with 78% T8993G, and her aunt died at age 1 with over 
95% mutant ATP6 (Tautch et al., 1992).  This study 
indicated that a large percentage of mutant ATP6 was 
required to cause either NARP or LS. 
 Subsequent studies conducted on a larger 
scale, including the one by White et al. (1999) that 
evaluated T8993G heteroplasmy in 56 pedigrees with 
LS and/or NARP, set the threshold for NARP at 70% to 
90% mutant ATP6 and LS at any dosage above 90% to 
95% (Schon et al., 2001).  If we return to the Tautch et 
al. study, it is interesting to note that the NARP mother 
had variable heteroplasmy of the T8993G mutation 
throughout her tissues (1992).  As detailed in their 
manuscript, this is likely due to a random asymmetrical 
distribution of mutant mitochondrial DNA during mitotic 
cell divisions (Tautch et al., 1992).  Perhaps, during 
development the mutant and wild-type mitochondria 
randomly separated unequally and the skin fibroblasts 
received 71% T8993G while the lymphoblasts inherited 
only 39% of the mutant mitochondrial DNA as in the 
Tautch et al. study (1992).  However, all studies of 
NARP and LS patients have demonstrated that the 
afflicted individuals harbor 70% to 90% for NARP and 
90% to 95% for LS on average with no significant 
difference between the T8993G and T8993C mutations 
(Tautch et al., 1992; White et al., 1999; Schon et al., 
2001). 
 At the molecular genetics level, ATP6 is like 
all mitochondrial genes in that it is composed of only 
coding DNA that cannot be alternatively spliced 
(Albert’s et al., 2004).  Interestingly, the triplet code for 
amino acids in the mitochondrial genome is different 
from that of the nucleus.  Therefore, several studies to 
be discussed will allude to their need to alter the 
nucleotide sequence of ATP6 in order to dictate the 
correct amino acid sequence when allotopically 
expressed in the nucleus of mammalian cells. 
 
Effects of T8993G on ATP Synthesis, and ATP 
Synthase Structure, Assembly, and Catalytic 
Activities 
 
It is obvious that ATP6 plays a critical role in ATP 
synthesis because it forms the channel for proton flow 
through ATP synthase and regulates the rotation of the 
c-ring as a result.  As stated earlier, LS and NARP 
syndromes both result from dysfunction of the ATP6 
gene, and their pathology is neurodegeneration.  Once 
the heteroplasmic effects of mutant ATP6 were 
investigated, the next gap in knowledge was whether a 
decrease in ATP synthesis is correlated with the LS and 
NARP pathology.  Based on the logic that extremely 
high demand for ATP by the brain is not satisfied by 
dysfunctional ATP synthase, initial studies attempted to 
measure ATP production as well as other 
characteristics of respiration in the cells of LS and 
NARP patients. 
Trounce et al. aimed to determine if 
lymphoblasts from LS patients had decreased ADP 
stimulated respiration (state III respiration) by analyzing 
the respiration rate and ADP phosphoralated to oxygen 
molecules reduced ratio (ADP/O) (1994).  Their results 
indicated that lymphoblasts harboring between 95% 
and 100% T8993G DNA had a 26% to 50% decrease in 
respiration rate, and 30% to 40% decrease in the 
ADP/O ratio.  In addition, if the same lymphoblasts 
were enucleated and then fused with mitochondrial 
DNA deficient 0 cells to create a cytoplasmic hybrid 
(cybrid), the T8993G homoplasmic mutants had a 
decreased respiration rate and ADP/O ratio similar to 
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that of the lymphoblasts (Trounce et al., 1994).  These 
results provided a critical demonstration of the ability of 
the T8993G mutation to reduce ATP synthesis and 
specifically, indicated a dysfunctional proton channel as 
the underlying cause. 
 Though a decrease in ATP synthesis was 
linked to the T8993G mutation, subsequent study by 
Houstek et al. further characterized the effects of this 
mutation on ATP synthase specifically (1995).  Using 
skin fibroblasts containing 99% T8993G DNA, they re-
affirmed the Trounce et al. (1994) findings of decreased 
ATP synthesis but, more importantly, analyzed the 
effect of the mutation on the assembly of ATP synthase 
(Houstek et al., 1995).  Incorporating mutant cells from 
the heart, kidney, muscle, and liver into their study, they 
found very little ATP synthase existing in the normal 
620 kDa form and many smaller complexes between 
150 kDa and 460 kDa.  When immunoprecipitating the 
F0 and F1 subunits individually, the F0 concentration was 
significantly reduced in certain tissues (Houstek et al., 
1995).  These results raise the possibility that the 
T8993G mutation may be detrimental as a result of it 
preventing proper ATP synthase complex assembly, 
rather than altering the properties of the proton channel 
itself (Houstek et al., 1995). 
 To fill help fill this gap in knowledge and solve 
the emerging controversy, Garcia et al. evaluated the 
effects of T8993G on ATP synthase function and 
assembly and determined if a reduction in proton flow 
through ATP6 is the prominent cause of decreased 
ATP synthesis (2000).  When the potential across the 
inner-mitochondrial membrane was measured in 
fibroblasts containing either 91% or 100% T8993G 
DNA, they found that the potential was decreased 
compared to controls (Garcia et al., 2000).  In addition, 
ATP hydrolysis was similar between mutants and 
controls, which indicates that the enzyme was 
assembled (Garcia et al., 2000).    The most significant 
finding was that the potential across the membrane is 
reduced when T8993G is present, indicating that there 
is reduction in proton flow through ATP6 (Garcia et al., 
2000).  Thus, Garcia et al. concluded that the mutation 
alters the catalytic activity of ATP6 rather then the 
stability or assembly of the enzyme, as previously 
thought (2000).  This finding contradicts the results of 
Houstek et al. (1995). 
 The debate over whether the mutation alters 
ATP synthase catalysis or assembly/structure led to 
several studies.  First, Baracca et al. published a 
manuscript supporting Garcia et al. (2000) that directly 
analyzed the rate of active proton pumping through 
ATP6 as well as overall ATP synthase activity, ATP 
hydrolysis, and ATP synthesis in T8993G sub-
mitochondrial particles isolated from platelets (Baracca 
et al., 2000).  ATP hydrolysis was unaffected, ATP 
synthesis was decreased by ~ 20X, whole enzyme 
function was decreased, but proton pumping was 
unaffected in mutants (Baracca et al., 2000).  Thus, 
they concluded that the enzyme was assembled with a 
small structural alteration in T8993G ATP6 that reduced 
proton flow and ATP synthesis.  Interestingly, this and 
the Garcia et al. (2000) study relied on the logic that if 
the ATP hydrolysis function is the same as controls, 
then the enzyme must be properly assembled. 
 Within a year of the Garcia et al. (2000) and 
Baracca et al. (2000) studies, Nijtmans et al. conducted 
research on the assembly of the ATP synthase 
holoenzyme in osteosarcoma cells transformed with 
T8993G mitochondria (2001).  Using immunoblots to 
detect the proper assembly of ATP synthase, they 
showed that the mutant enzyme existed in several 
different sub-complexes (Nijtmans et al., 2001).  This 
illustrates that the mutant ATP synthase is both 
improperly assembled and less stable (Nijtmans et al., 
2001).  Consequently, they concluded that the failure 
for proper ATP synthase assembly and decreased 
stability likely contributed to disease pathology, along 
with a decrease in catalytic function.  Thus, the debate 
arguably ended between the two differing hypotheses 
because evidence supported the combination of 
disassembly/decreased stability and catalytic 
dysfunction as synergistic causes of impaired ATP 
synthesis (Nijtmans et al., 2001; Baracca et al., 2000; 
Garcia et al., 2000; Houstek et al., 1995). 
  
Evaluation of ATP6 in E. coli 
 
The ATP synthase enzyme in humans exhibits an 
incredible degree of similarity to that of E. coli (Alberts 
et al., 2004).  Therefore, E. coli serves as an ideal 
model for studying ATP synthase activity and 
characteristics, though, mammalian cybrids remain the 
principal model.  The only model of LS and NARP 
syndrome outside of mammalian cells was created by 
Hartzog and Cain (2003).  They transformed ATP6 
deficient E. coli with the leucine156 to arginine 
substitution that is identical to that of T8993G (Hartzog 
and Cain, 2003).  When culture growth was measured, 
mutant cells were unable to grow, therefore, indicating 
the loss of ATP synthesis (Hartzog and Cain, 2003).  In 
addition, when the F1 portion was removed and 
functional F0 remained, the proton conductance through 
the channel was not distinguishable from negative 
controls (Hartzog and Cain, 2003).  These results 
mirrored those found in mammalian cells and cybrids, 
demonstrating the remarkable similarity between 
human and bacterial ATP synthase. 
 
Altering the Cellular Content of T8993G In Vivo 
 
Unlike the static nuclear genotype, the mitochondrial 
genetic makeup of a tissue or cell culture changes 
during mitotic divisions due to the assortment and 
divisions of individual mitochondria.  Whether this 
model could be used as a line of evidence suggesting 
that an individual with the T8993G mutation may later 
develop a more wild-type phenotype remained 
unknown until 1999.  Manfredi et al. employed a line of 
cybrids heteroplasmic for T8993G to examine the 
changes in mutant dosage over time (1999).  They 
used the mitochondrial ATP synthase inhibitor 
oligomycin and the respiratory straining galactose 
carbon source to stress a culture of heteroplasmic 
cybrids.  When the selective media was removed and 
the cells were allowed to recover, the percentage of 
T8993G within each cell decreased by 12% (Manfredi 
et al., 1999).  Cybrid divisions were not a rapidly 
occurring event during the study, indicating that intra-
cellular rather than inter-cellular selection for wild-type 
mtDNA was occurring (Manfredi et al., 1999).  The 
authors attribute this to the T8993G mutation possibly 
slowing or impairing mitochondrial division/replication.  
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Over time this would lead to a decrease of T8993G 
DNA (Manfredi et al., 1999). 
 If these findings are applied to an LS patient 
or NARP patient, development and cellular growth 
could reduce the percentage of mutant DNA.  The 
Manfredi et al. results do not make constant cell 
division necessary for this to occur because selection 
occurs intra-cellularly.  Thus, the cell simply needs to 
grow.   
 
Oxidative Stress, Apoptosis, and T8993G ATP6 
 
Oxidative stress resulting from the generation of 
reactive oxygen species (ROS) in dysfunctional 
mitochondria or in response to environmental toxins 
can produce a variety of detrimental effects or 
apoptosis (Alberts et al., 2004).  Because T8993G has 
such profound effects on ATP synthesis and leads to 
cell death if heteroplasmically high, researchers 
believed it was linked to oxidative stress and that may 
be the ultimate cause of neuronal atrophy (Geromel et 
al., 2001; Mattiazzi et al., 2004). 
 Using cultures of skin fibroblasts, Geromel et 
al. aimed to determine if cells from ATP synthase 
deficient patients with >90% T8993G were dieing from 
apoptosis (2001).  Cells were stained with the general 
apoptotic marker annexin V, and then with TUNEL to 
reveal the presence of fragmented DNA (Geromel et 
al., 2001).  Many previous studies have linked the 
overproduction of superoxides to causing apoptosis 
thus, they tested and found an elevated presence of the 
superoxide dismutase enzymes (SODs) that scavenge 
the free radicals (Geromel et al., 2001).  In order to link 
ROS accumulation/oxidative stress to instigating 
apoptosis the mutant fibroblasts were treated with 
TAPBN, which reduces free radicals (i.e. an 
antioxidant), and then stained with TUNEL (Geromel et 
al., 2001).  Interestingly, elevated SOD expression and 
TAPBN rescued the cells from apoptosis (Geromel et 
al., 2001).  These experiments provided the first 
evidence indicating that oxidative stress is involved in 
triggering apoptosis in mutant ATP6 cells and that they 
do not die simply from running out of energy (Geromel 
et al., 2001). 
 As a result of anti-oxidant treatment rescuing 
mutant ATP6 cells from apoptosis, Mattiazzi et al. 
examined the effects of anti-oxidants on ATP synthesis 
(2004).  They created cybrids formed by the fusion of 
mtDNA deficient osteosarcoma cells with enucleated 
platelet cells from NARP or LS individuals (Mattiazzi et 
al., 2004).  It was found that those cells produced 
elevated levels of ROS that damaged mitochondrial 
lipids and increased levels of superoxide dismutases 
(Mattiazzi et al., 2004).  The T8993G mutation was also 
found to cause dysfunction in non-mutated complexes 
of the electron-transport chain, further contributing to 
decreased ATP synthesis (Mattiazzi et al., 2004).   
Remarkably, treatment of mutant cybrids with 
NAC and DHLPA (antioxidants) reduced the amount of 
ROS and increased ATP synthesis (Mattiazzi et al., 
2004).  It is feasible that this finding implicates ROS 
species as electron-transport chain disruptors because 
removing them restores some ATP synthesis (Mattiazzi 
et al., 2004).  Lastly, in support of the decreased proton 
flow through ATP6 hypothesis they found an increased 
matrix pH in mutants as would be expected if protons 
were not flowing into it (Mattiazzi et al., 2004). 
 
Effects of Mutant ATP6 on Tumor Growth 
 
In the vast majority of cancer cells, there is some 
mutation within the mitochondrial genome (Shidara et 
al., 2005).  Based on this knowledge, Shidara et al. 
observed the role of T8993G ATP6 in tumor cell growth 
in mice (2005).  HeLa cells (immortal cell line created 
from cervical cancer) were fused with enucleated 
T8993G cells from patients with NARP to form cybrids 
(Shidara et al., 2005).  These HeLa cybrids were 
transplanted into mice and tumor growth was compared 
with mice receiving non-cybrid HeLa cells (Shidara et 
al., 2005).  Surprisingly, mutant ATP6 led to faster 
tumor growth and decreased apoptosis compared to 
WT ATP6 (Shidara et al., 2005).   
As discussed previously, the T8993G leads 
to an increase in ROS production, reduced ATP 
synthesis, and apoptosis, yet why is it that cancerous 
cells often have dysfunctional mitochondria or even lost 
ATP synthase function as in renal carcinomas 
(Mattiazzi et al., 2004; Shidara et al., 2005; Simonnet et 
al., 2002)?  Shidara et al. attribute this discrepancy with 
the Mattiazzi et al. study as the result of physiological 
differences between fibroblasts and HeLa cells (2005).  
HeLa cells satisfy their energy requirements using the 
glycolytic reactions more than oxidative-
phosphoralation in contrast to fibroblasts that perform 
the opposite (Shidara et al., 2005).  However, this 
finding is significant because if a cell becomes 
cancerous it is possible that the T8993G mutation will 
exacerbate tumor growth. 
 
Therapeutic Intervention 
 
Currently, there are no truly effective therapies for LS 
and NARP syndromes.  However, from the 
aforementioned research a novel possibility for 
therapeutic intervention arises; the introduction of 
antioxidants and/or over expression of SOD enzymes 
(Geromel et al., 2001; Mattiazzi et al., 2004).  If patients 
were able to absorb significant quantities of 
antioxidants into their cells, it may alleviate some of 
their symptoms and be especially beneficial to NARP 
patients.  For LS patients to survive gene therapy 
intervention is needed because they die from the 
disease in infancy.   
A study by Manfredi et al. may have revealed 
the key to treating the disease (2002).  Their research 
team converted the ATP6 codons into those compatible 
with the differing universal genetic code of the nucleus 
for amino acids and attached a mitochondrial targeting 
sequence (Manfredi et al., 2002).  This gene 
constructed of WT ATP6 was cloned into a vector and 
either transfected chemically or through a modified 
adeno-associated virus (AAV) into the nucleus of 
human HEK (human embryonic kidney) cells 
homoplasmic for T8993G ATP6 mitochondrial DNA 
(Manfredi et al., 2002).  They found that the WT ATP6 
being transcribed in the nucleus was trafficked to the 
mitochondria and incorporated into ATP synthase 
(Manfredi et al., 2002).  These cells demonstrated a 
significant increase in ATP synthesis as a result of 
allotopically expressed WT ATP6 (Manfredi et al., 
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2002).  Thus, this profound finding may lead to the 
expression of WT ATP6 in LS and NARP patients 
(Manfredi et al., 2002).  Perhaps, since the disease can 
be prenatally diagnosed, transfection of developing 
cells will lead to increased distribution of the functional 
gene. However, it is important to note that the mutant 
form of ATP6 will still be expressed to some degree.  
 
Future Research 
 
A possibility for future research includes further 
examination of the effect of T8993G on oxidative stress, 
and if ROS accumulation decreases ATP synthesis 
more than the defective proton channel alone.  This will 
allow pharmaceutical companies to know how to direct 
their short-term research efforts to design the first 
therapeutics for LS and NARP syndromes.  A second 
possibility is continuing research on the effectiveness of 
nuclear transfection of LS and NARP patient cells with 
WT ATP6 using an adeno virus.  Because cells can 
tolerate a significant degree of mutant ATP6, as 
illustrated by the 90% T8993G threshold for LS, 
allowing cells to produce a few percent more of WT 
ATP6 may bring them back below threshold and 
eliminate symptoms altogether.   
 
Conclusion 
 
The debilitating or fatal conditions caused by mutation 
within the ATP6 subunit of ATP synthase are all the 
reason to continue research within the field of 
mitochondrial genetics.  This review has presented 
three major hypotheses that attempt to fill the central 
gap in knowledge, which is how the alteration of ATP6 
reduces ATP synthesis and causes disease.  First, ATP 
synthesis is decreased as a result of the failure of 
proper ATP synthase assembly and stability.  Second, 
the substitution of the charged amino acid arginine for 
neutral leucine causes the proton channel ATP6 forms 
to resist or prevent proton flow thereby decreasing c-
ring rotation and ATP synthesis.  Third, the T8993G 
mutation and its effects on ATP synthase result in the 
accumulation of ROS causing oxidative stress that 
induces apoptosis and reduces electron-transport chain 
function.  All three of these hypotheses are currently 
valid and widely accepted within the field, and it is likely 
that all are involved in disease pathogenesis.  Thus, the 
new model combines aspects of all these hypotheses 
and their supporting evidence to show that all are 
intrinsically related.  
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views expressed in Eukaryon do not necessarily reflect 
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and should be cited as such only with the consent of 
the author. 
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